Last reviewed · How we verify
HA Chemotherapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
HA Chemotherapy (HA Chemotherapy) — Duke University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HA Chemotherapy TARGET | HA Chemotherapy | Duke University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HA Chemotherapy CI watch — RSS
- HA Chemotherapy CI watch — Atom
- HA Chemotherapy CI watch — JSON
- HA Chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). HA Chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/ha-chemotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing